Comparison of Efficacy and Safety Outcomes of Generic Versus Original Fingolimod Products in Patients with Multiple Sclerosis from Buenos Aires, Argentina

被引：0
|
作者：
Chertcoff, Anibal [1 ]
Steinberg, Judith [1 ]
Carra, Adriana [1 ]
机构：
[1] Hosp Britan Buenos Aires, MS & Demyelinating Dis, Buenos Aires, DF, Argentina
来源：
NEUROLOGY | 2020年 / 94卷 / 15期
关键词：
D O I：
暂无
中图分类号：
R74 [神经病学与精神病学];
学科分类号：
摘要：
2847
引用
收藏
页数：3
相关论文
共 50 条
  • [31] Real-life data from efficacy of fingolimod treatment in multiple sclerosis patients in Turkey
    Terzi, M.
    Kurtuncu, M.
    Eraksoy, M.
    Karabudak, R.
    Tuncer, A.
    Altunrende, B.
    Akcali, A.
    Boz, C.
    Sevim, S.
    Nur, Y.
    Tamam, Y.
    Bitnel, M.
    Turan, O. F.
    Soysal, A.
    Ozerden, M.
    Terzi, Y.
    [J]. MULTIPLE SCLEROSIS JOURNAL, 2016, 22 : 310 - 310
  • [32] 24-Month Efficacy and Safety Outcomes from the TRANSFORMS Extension Study of Oral Fingolimod (FTY720) in Patients with Relapsing-Remitting Multiple Sclerosis
    Khatri, Bhupendra
    Barkhof, Frederik
    Comi, Giancarlo
    Hartung, Hans-Peter
    Kappos, Ludwig
    Montalban, Xavier
    Pelletier, Jean
    Stites, Tracy
    Wu, Stacy
    Holdbrook, Frederick
    Cohen, Jeffrey
    [J]. NEUROLOGY, 2010, 74 (09) : A239 - A239
  • [33] Innovative phase 3 NEOS study design evaluating efficacy and safety of ofatumumab and siponimod versus fingolimod in paediatric multiple sclerosis
    Gartner, J.
    Deiva, K.
    Graves, J.
    Hemingway, C.
    Karlsson, G.
    Su, W.
    Haring, D. A.
    Thomas, M.
    Li, J.
    Hours-Zesiger, P.
    Krupp, L.
    [J]. MULTIPLE SCLEROSIS JOURNAL, 2021, 27 (2_SUPPL) : 198 - 199
  • [34] Comparison of the efficacy and retention of Natalizumab vs. Fingolimod in Cypriot patients with relapsing remitting multiple sclerosis.
    Kkolou, E.
    Leonidou, E.
    Gaglia, E.
    Pantzaris, M.
    [J]. EUROPEAN JOURNAL OF NEUROLOGY, 2016, 23 : 198 - 198
  • [35] Safety of fingolimod in patients with relapsing remitting multiple sclerosis: A descriptive analysis of data from the EudraVigilance database
    Nikitina, Victoria
    Laurini, Greta Santi
    Montanaro, Nicola
    Motola, Domenico
    [J]. JOURNAL OF THE NEUROLOGICAL SCIENCES, 2024, 463
  • [36] Clinical and Demographic Characteristics and Two-Year Efficacy and Safety Data of 508 Multiple Sclerosis Patients with Fingolimod Treatment
    Terzi, Murat
    Helvaci, Elif Merve
    Sen, Sedat
    Boz, Cavit
    Cilingir, Vedat
    Akcali, Aylin
    Beckmann, Yesim
    Uzunkopru, Cihat
    Turkoglu, Recai
    Yuceyar, Nur
    Efendi, Husnu
    Bunul, Sena Destan
    Seferoglu, Meral
    Kotan, Dilcan
    Guler, Sibel
    Balci, Belgin Petek
    Ozturk, Bilgin
    Mungan, Semra
    Icen, Nilufer Kale
    Omerhoca, Sami
    Yurtogullari, Sukran
    Sevim, Serhan
    Turkoglu, Sule Aydin
    Cam, Mustafa
    Yetkin, Mehmet Fatih
    Yoldas, Tahir Kurtulus
    Sivaci, Ali Ozhan
    Gokce, Seyda Figul
    Gursoy, Esra
    Unal, Aysun
    Bilge, Nuray
    Agan, Kadriye
    Toprak, Munire Kilinc
    Kocer, Belgin
    Sezer, Gokce
    Terzi, Yuksel
    [J]. NOROPSIKIYATRI ARSIVI-ARCHIVES OF NEUROPSYCHIATRY, 2023, 60 (01): : 23 - 27
  • [37] Review Of The Safety, Efficacy And Tolerability Of Fingolimod In The Treatment Of Pediatric Patients With Relapsing-Remitting Forms Of Multiple Sclerosis (RRMS)
    Feng, Jenny
    Rensel, Mary
    [J]. PEDIATRIC HEALTH MEDICINE AND THERAPEUTICS, 2019, 10 : 141 - 146
  • [38] Safety of switching from natalizumab straight into fingolimod in a group of JCV-positive patients with multiple sclerosis
    Fragoso, Yara Dadalti
    Alves-Leon, Soniza Vieira
    Becker, Jefferson
    Bidin Brooks, Joseph Bruno
    Correa, Eber Castro
    Damasceno, Alfredo
    da Gama, Paulo Diniz
    da Gama, Rodrigo Assad
    da Cunha Matta, Andre Palma
    Maciel, Ernane Pires
    d'Avila Winckler, Thereza Cristina
    [J]. ARQUIVOS DE NEURO-PSIQUIATRIA, 2016, 74 (08) : 650 - 652
  • [39] Immune cell profiles and clinical and safety outcomes with fingolimod in the 12 month fluent study of patients with relapsing multiple sclerosis
    Mao-Draayer, Y.
    Cohen, J.
    Bar-Or, A.
    Han, M.
    Singer, B.
    Kolodny, S.
    Elam, C.
    Meng, X.
    Ziehn, M.
    Cree, B.
    [J]. MULTIPLE SCLEROSIS JOURNAL, 2020, 26 (3_SUPPL) : 221 - 221
  • [40] REAL-WORLD ASSESSMENT OF EFFICACY AND SAFETY OF NATALIZUMAB VERSUS FINGOLIMOD IN PATIENTS WITH RELAPSING-REMITTING MULTIPLE SCLEROSIS: SYSTEMATIC REVIEW AND META-ANALYSIS
    Almalki, Z.
    [J]. VALUE IN HEALTH, 2023, 26 (06) : S21 - S21
12345